Research programme: dioxygenase inhibitors - NewLink Genetics

Drug Profile

Research programme: dioxygenase inhibitors - NewLink Genetics

Alternative Names: Ethyl pyruvate - NewLink Genetics; Indoleamine-2,3-dioxygenase (IDO) pathway inhibitors - NewLink Genetics; NLG-802; Tryptophan-2,3-dioxygenase inhibitors - NewLink Genetics

Latest Information Update: 22 Oct 2014

Price : $50

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Genentech; Lankenau Institute for Medical Research; NewLink Genetics Corporation
  • Class Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Hepatitis C; HIV infections

Most Recent Events

  • 20 Oct 2014 NewLink Genetics enters into a research collaboration with Genentech for the discovery of IDO/TDO compounds
  • 18 Dec 2013 This programme is still active
  • 24 Sep 2012 Preclinical development is ongoing for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top